Dr hab. n. med. Jakub Dobruch, FEBU – Liquid Biopsy

Dr hab. n. med. Jakub Dobruch, FEBU. Urological Review, The Polish Association of Urology bimonthly magazine. No. 5/2016

Liquid Biopsy is an example of a new kind of research that could revolutionize cancer detection and treatment of patients affected.

By | November 14th, 2016|Medical publications|0 Comments

Advanced Cancer Diagnostics Showcasingat 2016 NCRI Cancer Conference 6-9 November 2016

Chronix Biomedical’s Ireland & UK distributors Advanced Cancer Diagnostics will be attending and showcasing the latest Chronix diagnostic tests: Second Opinion Prostate Cancer Evaluation Test Second Opinion Breast Cancer Evaluation Test Delta Dot Treatment Monitoring Test CNI Cancer Evaluation Test Please visit our booth #79 at The BT Convention Centre, Kings Dock, Waterfront, Liverpool L3 [...]

By | November 3rd, 2016|Events|0 Comments

ASCO 2016

“Tumor cell-free DNA copy number instability (CNI) predicts therapeutic response to immunotherapy prior to cycle 2” , was presented at the American Society of Clinical Oncology (‘ASCO’) Annual Meeting 2016 on 5 June 2016 at McCormick Place in Chicago, Illinois. The abstract and poster presentation describe the work conducted by independent oncologists in a blinded [...]

By | November 3rd, 2016|Events|0 Comments

Chronix Biomedical updates on progress with prostate and pancreatic cancer validation studies

Chronix Biomedical

Chronix Biomedical, Inc., a developer of novel cancer blood-based molecular diagnostics, is pleased to update investors on the progress of two clinical studies...

By | November 3rd, 2016|Chronix news|0 Comments

Experts from Chronix Biomedical about the CNI Tests – Innovative Cancer Diagnostics

#TheTurningPointInCancerFight

By | November 3rd, 2016|Video|0 Comments

Prof. Piotr Radziszewski – New generation oncological biomarkers – focusing on Chronix company

Prof. Piotr Radziszewski. New generation oncological biomarkers – focusing on Chronix company. 1.10.2016.

We present a lecture delivered at the 5th Polish women and men health debate according to Medical guidelines – kidney cancer, bladder cancer.

By | November 3rd, 2016|Medical publications, Video|0 Comments

First published results in breast cancer

Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 2010; 8:335-42.

Chronix has first used the NGS technology for investigation into the use in breast cancer with very promising results.

By | November 3rd, 2016|Medical publications|0 Comments

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor cell-free DNA copy number instability (CNI) to predict therapeutic response to immunotherapy prior to cycle 2. J ClinOncol 34, 2016 (suppl; abstr 3027).

We measured CNAs changes during treatment by computing a genomic copy number instability index (CNI) of cfDNA and Treg-specific demethylation region (TSDR) as measure for Tregs% of leukocytes compared to response.

By | November 3rd, 2016|Medical publications|0 Comments

Predicting Treatment Outcomes in Chemotherapy

Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.

Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.

By | November 3rd, 2016|Medical publications|0 Comments

Prostate Cancer Blood Test

Schütz, E., et al. Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer. Clinical Chemistry 2015; 61: 239-248.

Tumor-specific cell free DNA (cfDNA) present in serum and plasma provides a real-time, easily accessible surrogate. We demonstrated variations in the number of cfDNA sequences circulating in the serum of patients with prostate cancer compared with healthy controls.

By | November 3rd, 2016|Medical publications|0 Comments